Rodolfo Bordoni1, Fortunato Ciardiello2, Joachim von Pawel3, Diego Cortinovis4, Thomas Karagiannis5, Marcus Ballinger5, Alan Sandler5, Wei Yu5, Pei He5, Christina Matheny5, Federico Felizzi6, Achim Rittmeyer7. 1. Georgia Cancer Specialists and Northside Hospital Cancer Institute, Sandy Springs, GA. Electronic address: Rodolfo.Bordoni@aol.com. 2. Università degli Studi della Campania Luigi Vanvitelli, Santa Maria Capua Vetere, Italy. 3. Asklepios Fachkliniken München-Gauting, Gauting, Germany. 4. Ospedale San Gerardo di Monza, Monza, Italy. 5. Genentech Inc, South San Francisco, CA. 6. F. Hoffmann-La Roche Ltd, Basel, Switzerland. 7. LKI Lungenfachklinik Immenhausen, Immenhausen, Germany.
Abstract
BACKGROUND: The randomized phase III OAK (a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small-cell lung cancer [NSCLC] who have failed platinum-containing therapy) trial investigated the anti-programmed cell death ligand 1 (PD-L1) antibody atezolizumab for advanced or metastatic, previously treated, NSCLC. Atezolizumab significantly improved overall survival (OS) compared with docetaxel (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.62-0.87; P = .0003; median OS, 13.8 vs. 9.6 months, respectively). Patient-reported outcomes (PROs) were collected to evaluate disease-related symptoms and health-related quality of life (HRQoL) to support the finding of a survival benefit. PATIENTS AND METHODS: The first 850 patients were randomized to receive atezolizumab (1200 mg every 3 weeks) or docetaxel (75 mg/m2 every 3 weeks). PROs were collected on day 1 of cycle 1, day 1 of every subsequent cycle, and at the end-of-treatment visit for patients who completed ≥ 1 baseline and 1 postbaseline PRO assessment. The European Organisation for the Research and Treatment of Cancer QoL questionnaire and lung cancer module were used to assess PROs. RESULTS:Atezolizumab delayed the time to deterioration (TTD) in physical function (HR, 0.75; 95% CI, 0.58-0.98) and role function (HR, 0.79; 95% CI, 0.62-1.00) and numerically improved patients' HRQoL from baseline compared with docetaxel. Atezolizumab also prolonged the TTD in chest pain (HR, 0.71; 95% CI, 0.49-1.05; P = .0823), although both arms showed an objective reduction relative to baseline. Overall, the patients had no clinically significant worsening in treatment-related symptoms, although the scores favored atezolizumab. CONCLUSION: These PRO data support the clinical benefit of atezolizumab in patients with previously treated advanced or metastatic NSCLC. Atezolizumab prolonged the TTD of patients' limitations in role and physical functions compared with docetaxel.
RCT Entities:
BACKGROUND: The randomized phase III OAK (a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small-cell lung cancer [NSCLC] who have failed platinum-containing therapy) trial investigated the anti-programmed cell death ligand 1 (PD-L1) antibody atezolizumab for advanced or metastatic, previously treated, NSCLC. Atezolizumab significantly improved overall survival (OS) compared with docetaxel (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.62-0.87; P = .0003; median OS, 13.8 vs. 9.6 months, respectively). Patient-reported outcomes (PROs) were collected to evaluate disease-related symptoms and health-related quality of life (HRQoL) to support the finding of a survival benefit. PATIENTS AND METHODS: The first 850 patients were randomized to receive atezolizumab (1200 mg every 3 weeks) or docetaxel (75 mg/m2 every 3 weeks). PROs were collected on day 1 of cycle 1, day 1 of every subsequent cycle, and at the end-of-treatment visit for patients who completed ≥ 1 baseline and 1 postbaseline PRO assessment. The European Organisation for the Research and Treatment of Cancer QoL questionnaire and lung cancer module were used to assess PROs. RESULTS:Atezolizumab delayed the time to deterioration (TTD) in physical function (HR, 0.75; 95% CI, 0.58-0.98) and role function (HR, 0.79; 95% CI, 0.62-1.00) and numerically improved patients' HRQoL from baseline compared with docetaxel. Atezolizumab also prolonged the TTD in chest pain (HR, 0.71; 95% CI, 0.49-1.05; P = .0823), although both arms showed an objective reduction relative to baseline. Overall, the patients had no clinically significant worsening in treatment-related symptoms, although the scores favored atezolizumab. CONCLUSION: These PRO data support the clinical benefit of atezolizumab in patients with previously treated advanced or metastatic NSCLC. Atezolizumab prolonged the TTD of patients' limitations in role and physical functions compared with docetaxel.
Authors: Laurie E Steffen McLouth; Thomas W Lycan; Beverly J Levine; Jennifer Gabbard; Jimmy Ruiz; Michael Farris; Stefan C Grant; Nicholas M Pajewski; Kathryn E Weaver; W Jeffrey Petty Journal: Clin Lung Cancer Date: 2019-11-29 Impact factor: 4.785
Authors: Brian D Gonzalez; Sarah L Eisel; Kristina E Bowles; Aasha I Hoogland; Brian W James; Brent J Small; Susan Sharpe; Kelly A Hyland; Hailey W Bulls; Shannon M Christy; Jori Mansfield; Ashley M Nelson; Raviteja Alla; Kelly Maharaj; Brittany Kennedy; Elizabeth Lafranchise; Noelle L Williams; Sarah Jennewein; Laura B Oswald; Michael A Postow; Adam P Dicker; Heather S L Jim Journal: J Natl Cancer Inst Date: 2022-06-13 Impact factor: 11.816
Authors: Laurie E McLouth; Chandylen L Nightingale; Beverly J Levine; Jessica L Burris; Jean A McDougall; Thomas W Lycan; Jennifer Gabbard; Jimmy Ruiz; Michael Farris; Arthur W Blackstock; Stefan C Grant; W Jeffrey Petty; Kathryn E Weaver Journal: JCO Oncol Pract Date: 2021-02-04
Authors: Martin Reck; Thomas Wehler; Francisco Orlandi; Naoyuki Nogami; Carlo Barone; Denis Moro-Sibilot; Mikhail Shtivelband; Jose Luis González Larriba; Jeffrey Rothenstein; Martin Früh; Wei Yu; Yu Deng; Shelley Coleman; Geetha Shankar; Hina Patel; Claudia Kelsch; Anthony Lee; Elisabeth Piault; Mark A Socinski Journal: J Clin Oncol Date: 2020-05-27 Impact factor: 44.544
Authors: Sabina Asensio-Cuesta; Ángel Sánchez-García; J Alberto Conejero; Carlos Saez; Alejandro Rivero-Rodriguez; Juan M García-Gómez Journal: Int J Environ Res Public Health Date: 2019-02-05 Impact factor: 3.390